Testicular cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 6, 2009, Pages 672-693

  Motzer, Robert J ^a   Agarwal, Neeraj ^b   Beard, Clair ^c   Bolger, Graeme B ^d   Boston, Barry ^e   Carducci, Michael A ^f   Choueiri, Toni K ^c   Figlin, Robert A ^g   Fishman, Mayer ^h   Hancock, Steven L ⁱ   Hudes, Gary R ^j   Jonasch, Eric ^k   Kessinger, Anne ^l   Kuzel, Timothy M ^m   Lange, Paul H ⁿ   Levine, Ellis G ^o   Margolin, Kim A ⁿ   Michaelson, M Dror ^p   Olencki, Thomas ^q   Pili, Roberto ^o   Redman, Bruce G ^r   Robertson, Cary N ^s   Schwartz, Lawrence H ^a   Sheinfeld, Joel ^a   Wang, Jue ^l   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Dana Farber Brigham and Women's Cancer Center   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l NEBRASKA MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^q OHIO STATE UNIVERSITY   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s DUKE CANCER INSTITUTE   (United States)

more..

Author keywords

Alpha fetoprotein; Cisplatin; Germ cell tumors; Human chorionic gonadotropin; Lactate dehydrogenase; NCCN Clinical Practice Guidelines; Nonseminoma; Seminoma; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; OXALIPLATIN; PACLITAXEL; VINBLASTINE;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; GERM CELL TUMOR; HEMATOLOGIC DISEASE; HUMAN; LUNG FIBROSIS; LYMPH NODE DISSECTION; MEDIASTINAL SEMINOMA; METASTATIC GERM CELL TUMOR; MULTIPLE CYCLE TREATMENT; NEUROMUSCULAR DISEASE; NON SEMINOMATOUS GERMINOMA; PRACTICE GUIDELINE; PROGNOSIS; RADIODIAGNOSIS; RAYNAUD PHENOMENON; REVIEW; SALVAGE THERAPY; SEMINOMA; TESTIS CANCER; ARTICLE; MALE; METASTASIS; NEOPLASM; PATHOLOGY; RISK ASSESSMENT; TESTIS TUMOR;

HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 67651235907     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0047     Document Type: Review

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Jones RH, Vasey PA. Part I: testicular cancer - management of early disease. Lancet Oncol 2003;4:730-737. (Pubitemid 37527208)
3. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population based study of 29,515 US men. J Natl Cancer Inst 2005;97:1056-1066. (Pubitemid 41417922)
4. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-1208. (Pubitemid 46202277)
5. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366:293-300. (Pubitemid 41019418)
6. Oliver RT, Mead GM, Fogarty PJ, et al Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) [abstract]. J Clin Oncol 2008;26:(Suppl 1):Abstract 1.
7. Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: a 15 year review. Urol Oncol 2006;24:180-183.
8. Gospodarowicz M, Sturgeon JF, Jewitt MA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 1998;25:160-173. (Pubitemid 28201390)
9. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-1640.
10. Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-476.
11. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598-606. (Pubitemid 23105666)
12. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:9290-9294. (Pubitemid 46260186)
13. Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005;54:284-288. (Pubitemid 40523622)
14. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255-2262.
15. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998;14:454-460. (Pubitemid 26051007)
16. Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120-126. (Pubitemid 2029119)
17. Sheinfeld J, Herr H. Role of surgery in management of germ-cell tumors. Semin Oncol 1998;25:203-209. (Pubitemid 28201394)
18. Carver BS, Sheinfeld J. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol 2005;2:330-335. (Pubitemid 41122581)
19. Davis BE, Herr HW, Fair WR, et al. The management of patients with nonseminomatous germ-cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111-114.
20. Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296-1298. (Pubitemid 26081222)
21. Foster R, Bihrle R. Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control 2002;9:277-283. (Pubitemid 34921033)
22. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors. Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research 1998b;2:455-459.
23. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
24. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440. (Pubitemid 17079090)
25. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin vs vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ-cell tumors. J Clin Oncol 1988;6:1231-1238. (Pubitemid 18196800)
26. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-391.
27. Jones RH, Vasey PA. Part II: testicular cancer - management of advanced disease. Lancet Oncol 2003;4:738-747. (Pubitemid 37527209)
28. Toner GC, Motzer RJ. Poor prognosis germ-cell tumors: current status and future directions. Semin Oncol 1998;25:194-202. (Pubitemid 28201393)
29. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-546. (Pubitemid 18249627)
30. Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ-cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991;67:1305-1310.
31. McCaffrey J A, Mazumdar M, Bajorin DF, et al. Ifosfamide + cisplatin regimens as first-line salvage therapy in germ-cell tumors: response and survival (abstract). Proc Am Soc Clin Oncol 1996;14:Abstract 250.
32. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ-cell tumor. J Clin Oncol 1998;16:2500-2504. (Pubitemid 28309047)
33. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ-cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84:1703-1709.
34. Beyer J, Kramer A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-2645. (Pubitemid 26329647)
35. Wood DP, Herr H, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with non-seminomatous germ-cell tumors and elevated serum tumor markers. Cancer 1992;70:2354-2357.
36. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493-497. (Pubitemid 38444556)
37. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108-114. (Pubitemid 41095121)
38. De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006;50:1032-1038; discussion 1038-1039. (Pubitemid 44486485)